Endovascular denervation (EDN): From Hypertension to Non-Hypertension Diseases

Tao Pan; Qi Zhang; Jinhe Guo

doi:10.1016/j.jimed.2021.05.006

Endovascular denervation (EDN): From Hypertension to Non-Hypertension Diseases

J Interv Med. 2021 May 26;4(3):130-135. doi: 10.1016/j.jimed.2021.05.006. eCollection 2021 Aug.

Authors

Tao Pan¹, Qi Zhang¹, Jinhe Guo¹

Affiliation

¹ Center of Interventional Radiology & Vascular Surgery, Department of Radiology, Zhongda Hospital, Southeast University, 87 Dingjiaqiao Road, Nanjing, 210009, China.

Abstract

Recently, the use of endovascular denervation (EDN) to treat resistant hypertension has gained significant attention. In addition to reducing sympathetic activity, EDN might also have beneficial effects on pulmonary arterial hypertension, insulin resistance, chronic kidney disease, atrial fibrillation, heart failure, obstructive sleep apnea syndrome, loin pain hematuria syndrome, cancer pain and so on. In this article we will summarize the progress of EDN in clinical research.

Keywords: Clinical research; Endovascular denervation; Resistant hypertension; Sympathetic activity.